Theranostics 2017; 7(7):2065-2066. doi:10.7150/thno.20622


In Molecular Pursuit of Bone Metastasis by Fluciclovine PET

Liza Lindenberg1,2 ✉

1. Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
2. Adjunct Assistant Professor of Radiology/Assistant Professor of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD


Diagnosing bone metastases with traditional anatomic modalities, such as MRI and CT, is limited by sensitivity, and conventional bone radiotracers are only indirect markers of cancer activity. Fortunately, molecular imaging is uniquely capable of providing radiotracers such as fluciclovine and radiolabeled choline, that actually target tumors in the bone. The merits of research in imaging osseous metastases in animal models using these radiotracers and the implications for future clinical translation are discussed.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license ( See for full terms and conditions.
How to cite this article:
Lindenberg L. In Molecular Pursuit of Bone Metastasis by Fluciclovine PET. Theranostics 2017; 7(7):2065-2066. doi:10.7150/thno.20622. Available from